Genital in Medical Technology

BioVex Announces Regulatory Clearance to Commence a Clinical Study With ImmunoVEX HSV2; A Vaccine Candidate for Genital Herpes

... of its lead infectious disease candidate for genital herpes, ImmunoVEX HSV2. ImmunoVEX HSV2 is a ... HSV2 completely prevented all symptoms of genital herpes and triggered a powerful immune ... towards realizing this potential." About genital Herpes At least 45 million people over the age ...

Vical Receives NIH Grant for an Immunotherapeutic Herpes DNA Vaccine; Herpes Experts at University of Washington and University of Texas to Conduct Preclinical Development

... type 2 (HSV-2), a sexually transmitted virus which is the leading cause of genital herpes. The HSV-2 vaccine will also be evaluated with Vical's novel ... HSV-2 is a member of the herpesvirus family, and is the leading cause of genital herpes worldwide. In the United States, HSV-2 infects some 1.6 million ...

BioVex to Report Phase I/II Clinical Trial Results for the Front Line Treatment of Head and Neck Cancer With OncoVEX GM-CSF at the 2009 American Society of Clinical Oncology Meeting

... as stand alone therapy. An overview of the Phase II melanoma results is available on our website. The Company's second program is a vaccine for genital herpes, ImmunoVEX HSV2, which provides complete protection in animal models of the disease. The vaccine has been authorized to commence clinical ...

Indevus Pharmaceuticals Announces PRO 2000 Found to Show Promise in Large HIV Prevention Study

... simplex virus, chlamydia and the bacterium that causes gonorrhea. Vaginally applied PRO 2000 has been found to afford protection in mouse models for genital herpes infection and gonorrhea, and in a simian model for vaginal HIV infection. Prior to initiation of the HPTN 035 trial, PRO 2000 had undergone ...

Pivotal Data Published For First Biomarker Combination Test to Determine Risk of Ovarian Cancer in Women Who Present With Pelvic Mass

... of death from gynecologic cancers in the U.S. and the fifth-leading cause of cancer death in women. It accounts for 31% of cancers of the female genital organs. There are an estimated 22,000 new cases annually in the U.S. Women who are postmenopausal are at the greatest risk for ovarian cancer. In ...

Hologic Releases the Results of the Cervista(TM) HPV Clinical Trials

... The clinical and analytical performance of Cervista HPV high-risk test results are scheduled to be presented at the European Research Organization on genital Infection and Neoplasia (Eurogin) HPV conference in Nice, France on Saturday, November 15th 2008. Due to an early publication of the abstract by ...

Topical Treatment for Cold Sores Achieves Efficacy of Oral Drugs; Represents Paradigm Shift in the Treatment of Skin Infections

... the herpes simplex virus causes both cold sores and genital herpes, there is a strong potential that NB-001 will also be effective in treating genital lesions, she added. NanoBio is currently testing its pipeline of topical products against a wide range of skin infections including onychomycosis ...

Nventa Presents Findings on Proprietary Toll-like Receptor 3 (TLR3) Agonist, Poly-ICR, at World Vaccine Congress

... Poly-ICR into future internal product candidates, Nventa is pursuing the development of Poly-ICR for topical application for the treatment of genital warts (GW) and actinic keratosis, a premalignant condition of the skin. The company is also currently providing access to Poly-ICR to ...

Successful Results for Mymetics Corporation's Mucosal HIV/AIDS Vaccine Viral Challenge Significantly Exceeds Expectations

... challenged thirteen times with the chimeric SHIV. Female Chinese Macaca Mulata (macaques) were chosen as their infection by SHIV through the genital route closely resembles the observed human infection rate by HIV. The company expects to present the fully detailed results as well as the challenge ...

BioVex Reports Positive Phase II Clinical Trial Results of OncoVEX GM-CSF in Metastatic Melanoma at the 2008 American Society of Clinical Oncology Meeting

... (SPA) procedure and plans to make a second SPA submission for head & neck cancer later in the year. The Company's second program is a vaccine for genital herpes, ImmunoVEX HSV2, which provides complete protection in animal models of the disease. A Phase I study with ImmunoVEX HSV2 is scheduled to ...

BioVex to Report Phase II Clinical Trial Results of OncoVEX GM-CSF in Metastatic Melanoma at the 2008 American Society of Clinical Oncology Meeting

... (SPA) procedure and plans to make a second SPA submission for head & neck cancer later in the year. The Company's second program is a vaccine for genital herpes, ImmunoVEX HSV2, which provides complete protection in animal models of the disease. A Phase I study with ImmunoVEX HSV2 is scheduled to ...

BioVex Agrees SPA With the FDA for a Pivotal Study With OncoVEX(GM-CSF) in Metastatic Melanoma and Announces Presentation of Phase II Results at ASCO

... trial for melanoma and Phase I/II clinical trials for head & neck cancer and pancreatic cancer. The Company's second program is a vaccine for genital herpes, ImmunoVEX HSV2, which provides complete protection in animal models of the disease. A Phase I study with ImmunoVEX HSV2 is scheduled to ...

Gen-Probe Begins U.S. Clinical Study of Molecular Test for Human Papillomavirus, Which Causes Cervical Cancer

... and resolve without any clinical symptoms or consequences. However, a small number of HPV infections progress and result in disease ranging from genital warts to cervical cancer. Since most HPV infections do not result in cancer, there is a need for a more specific test to identify women at greater ...

Two Point of Care Tests From Quest Diagnostics Receive FDA 510(k) Clearance

... for Focus Diagnostics' HerpeSelect(R) Express(TM) HSV-2, a test for aiding in the diagnosis of the herpes simplex type-2 virus, the primary cause of genital herpes. This is the first step in the regulatory process that allows the companies to market the products and file for CLIA waivers, which would ...

The First Annual Cervical Cancer/HPV Conference Tackles Controversial Vaccine Issues and Encourages Advocacy

... Health and of the California STD/HIV Prevention Training center included: -- Currently, there are more than 20 million people infected with a genital HPV infection in the U.S. -- There are 6.2 million new HPV infections annually, with more than 80 percent of people (men and women) acquiring ...

Sexual Function Affected by Stem Cell Transplant According to Long-Term Study

... about changes in sensation, strategies for enhancing libido, and use of vaginal lubricants, dilators, or vibrators to assist with adapting to genital changes may help to maintain sexual responsiveness. This work was supported by grants from the National Cancer Institute. The American Society of ...

Gardasil Demonstrates Up to 100% Efficacy

... and vaginal lesions (VaIN 1-3 and VIN 1-3), and genital warts caused by Human Papillomavirus types 6, 11, ... be 100% efficacious against cervical lesions and genital warts after five years of follow ... by Gardasil® cause the vast majority of genital Human Papillomavirus diseases. It is estimated ...

New England Journal of Medicine Publishes New Data on Gardasil, Merck's Cervical Cancer Vaccine

... cancer cases and 90 percent of cases of genital warts. All four types cause a large number of ... neoplasia (VaIN) 2/3), and for the prevention of genital warts and low-grade cervical lesions (CIN 1) ... pre-cancers (VIN 1-3 and VaIN 1-3) and external genital warts caused by the four HPV types targeted by ...

Data Published in The Lancet Show Gardasil was 100 Percent Effective in Preventing High-Grade Vulvar and Vaginal Lesions Caused by HPV Types 16 and 18

... neoplasia (VaIN) 2/3), and for the prevention of genital warts and low-grade cervical lesions (CIN 1) ... not intended to be used for treatment of active genital warts; cervical cancer; CIN, VIN, or VaIN. ... period. Certain low-risk types of HPV cause genital warts and can lead to abnormal Pap results. ...

Mymetics' HIV Vaccine Demonstrates First-Ever Production of Neutralizing IgA Antibodies in Non-Human Primate Model

... expressing the HIV-1 gp41 peptide produced mucosal IgA antibodies in the genital and intestinal compartments. These mucosal antibodies were capable ... are the result of sexual transmission in which mucosal tissues from the genital and anorectal regions have been exposed to HIV-1 present in semen ...

Testing for Human Papillomavirus

... by nucleic acid sequence homology rather than serologic reactivity. genital HPVs are the most prevalent sexually transmitted pathogens. Of the ... associated with 99.7% of squamous cell cancers of the cervix. Most genital HPV infections in women produce transient squamous cell abnormalities of ...

Mymetics' HIV Vaccine Achieves Research Breakthrough, Eliciting Protective Antibody Response in Mucosal Tissues of Non-Human Primate Model

... Mymetics Vaccine Program Background Worldwide, over 85% of HIV infections are the result of sexual transmission in which mucosal tissues from the genital and anorectal regions have been exposed to HIV-1 present in semen or secretions. According to a recent report from the International AIDS Vaccine ...

Data from Investigator-Sponsored Trial of Oncophage Cancer Vaccine in Glioma Presented at American Association of Neurological Surgeons Annual Meeting

... indications; Aroplatin(TM) (L-NDDP), a liposomal, third-generation platinum chemotherapeutic; AG-707, a therapeutic vaccine for the treatment of genital herpes; and QS-21, an adjuvant being evaluated by Antigenics' corporate partners in several late-stage clinical trials. For more information, ...

Spectrum Pharmaceuticals Announces Data From Three Oncology Programs Presented at the American Association of Cancer Research Annual Meeting

... Efficacy of Cyclophosphamide and Cisplatin in Ovarian Tumor Bearing Mice Ovarian cancer represents the most malignant carcinoma of the female genital tract and is often diagnosed only after the disease has reached the advanced stage. Currently, primary therapy includes surgery followed by ...

Treatment with Copaxone Plus Minocycline Showed Substantial Reduction of Disease Activity in Patients with Active Relapsing-Remitting Multiple Sclerosis

... and well tolerated," she added. Minocycline is a broad-spectrum antibiotic, which is used to treat pneumonia, acne, and infections of the skin, genital and urinary systems, and the central nervous system. In a small proof-of-concept trial of 10 RRMS patients, minocycline demonstrated an 84 percent ...

Treatment with Copaxone Plus Minocycline Showed Substantial Reduction of Disease Activity in Patients with Active Relapsing-Remitting Multiple Sclerosis

... and well tolerated," she added. Minocycline is a broad-spectrum antibiotic, which is used to treat pneumonia, acne, and infections of the skin, genital and urinary systems, and the central nervous system. In a small proof-of-concept trial of 10 RRMS patients, minocycline demonstrated an 84 percent ...

Oncophage Cancer Vaccine Significantly Prolongs Recurrence-Free Survival by 45 Percent in Patients With Intermediate-Risk Kidney Cancer

... indications; Aroplatin(TM) (L-NDDP), a liposomal, third-generation platinum chemotherapeutic; AG-707, a therapeutic vaccine for the treatment of genital herpes; and QS-21, an adjuvant being evaluated by Antigenics' corporate partners in more than twenty indications, several in late-stage ...